CORONA Remedies Limited (CORONA) has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its Bhayla manufacturing facility in Ahmedabad. This certification covers both Oral Solid Dosage (OSD) and Women’s Hormone production lines. This milestone further strengthens CORONA’s manufacturing credentials and reaffirms its commitment to maintaining high standards of quality, compliance, and operational excellence.

Reaffirming the Philosophy of ‘One World, One Quality’

While India will remain the company’s primary market, contributing over 96% of its revenue, the ANVISA GMP certification further strengthens CORONA’s manufacturing credentials. This marks CORONA’s third major GMP accreditation, building on its EU-GMP approvals for the Women’s Hormone and OSD facilities and its EAEU-GMP certification for the OSD facility. Brazil represents one of the largest pharmaceutical markets in Latin America, with an estimated market size of USD 44 billion, presenting opportunities for pharmaceutical manufacturers with strong quality systems and regulatory capabilities.

Commitment to Quality and Compliance

Together, these recognitions reflect the company’s continued focus on strengthening quality systems, maintaining regulatory compliance, and fostering a culture of continuous improvement across its manufacturing operations. Commenting on this achievement, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited, said: “Quality has always been central to the way we work at CORONA Remedies. Our philosophy of ‘One World, One Quality’ reflects our belief that the standards we follow must remain consistent and uncompromised. The ANVISA GMP certification for our Bhayla manufacturing facility is an important recognition of the systems, discipline, and collective efforts that go into maintaining these standards. While India remains our primary market and the focus of our business, such accreditations further strengthen our manufacturing credentials and reaffirm our commitment to quality and compliance. We will continue to strengthen our capabilities and uphold the quality standards that guide everything we do.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

CORONA Remedies Limited (CORONA) announced its unaudited financial results for Q1FY27, delivering robust revenue and resilient margins, supported by consistent brand-building and enhanced operational efficiencies. The company reported a revenue of ₹422.4 Cr for Q1FY27, registering a growth of 21.9% Y-o-Y, driven by execution excellence and focused brand-building initiatives.

Financial Performance

The Profit After Tax (PAT) for Q1FY27 stood at ₹60.1 Cr, a growth of 30.1% Y-o-Y. PAT margins for Q1FY27 stood at 14.2%, an increase of 90 bps Y-o-Y. The EBITDA for the quarter was ₹93.1 Cr, showing a 33.5% Y-o-Y growth. The EBITDA margin improved to 22.0% from 20.1% in the same period last year.

Key Business Highlights

CORONA continues to be the fastest-growing company among the top 30 companies of the Indian Pharma Market (IPM) for the last 6 consecutive months, as per MAT June ’26. The company has also inaugurated and initiated the commercialization of its EU-GMP approved Female Hormone Manufacturing Facility based in Ahmedabad on June 30, 2026. Additionally, the integration of the acquired brand Wokadine is progressing smoothly from the supply and distribution perspectives.

Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “Q1 FY27 shows our commitment to consistent growth with operational excellence and brand building. With robust revenue growth and market rank improvement, we see positive outcomes of the strategies in place. We aim to move steadfast with our aligned focus on core therapies such as Women’s Healthcare, Cardio-diabetes, Pain Management, and Urology. We are also strengthening ourselves in Infertility and Biosimilar segments.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA gains 21.6% over three months and trades near its 52-week highs. The PEG of 2.33 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. The stock trades at 95% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.33 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

CORONA Remedies Limited has announced the inauguration and commercialisation of its state-of-the-art EU-GMP approved Hormone Manufacturing Facility in Bhayla, Ahmedabad. This facility marks a significant milestone in the company’s journey towards building globally benchmarked pharmaceutical manufacturing capabilities. The facility was inaugurated by Chairman, Dr. K. L. Mehta, alongside long-serving women employees of the organisation, symbolising CORONA’s enduring commitment to women’s health and the invaluable contribution of women in shaping the company’s success.

Responding to the Growing Need for Women’s Healthcare

As global attention towards women’s healthcare continues to grow, driven by greater awareness and diagnosis of hormonal disorders, increasing demand for fertility care and expanding focus on menopause management and hormone replacement therapies, the need for specialised, high-quality pharmaceutical manufacturing has become more critical than ever. Recognising this evolving need, CORONA Remedies has established one of India’s most advanced dedicated hormone manufacturing facilities, strengthening its capabilities to serve both domestic and international markets.

A Purpose-Built Manufacturing Ecosystem

Unlike conventional pharmaceutical manufacturing plants, dedicated hormone manufacturing requires complete segregation of operations, precision environmental controls, specialised containment technologies and highly trained personnel to ensure safe handling of potent hormone active pharmaceutical ingredients (APIs). CORONA’s integrated manufacturing platform supports multiple dosage forms—including tablets, soft gel capsules, ointments and gels—within a single specialised manufacturing ecosystem, enabling the company to cater to a broad spectrum of women’s healthcare therapies.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA gains 26.5% over three months and trades near its 52-week highs. The PEG of 2.19 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.2x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 11 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.19 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.